1. Changing the name of diabetes insipidus: a position statement of the working group to consider renaming diabetes insipidus
- Author
-
Hiroshi Arima, Timothy Cheetham, Mirjam Christ-Crain, Deborah L. Cooper, Juliana B. Drummond, Mark Gurnell, Miles Levy, Ann McCormack, John D. Newell-Price, Joseph G. Verbalis, and John Wass
- Subjects
Medicine ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
“What's in a name? That which we call a rose / By any other name would smell as sweet” (Juliet, from Romeo and Juliet by William Shakespeare). Shakespeare's implication is that a name is nothing but a word and it therefore represents a convention with no intrinsic meaning. Whilst this may be relevant to romantic literature, disease names do have real meanings, and consequences, in medicine. Hence, there must be a very good rational for changing the name of a disease that has a centuries-old historical context. A working group of representatives from national and international endocrinology and endocrine pediatric societies now proposes changing the name of “diabetes insipidus” to “Arginine Vasopressin Deficiency (AVP-D)” for central etiologies, and “Arginine Vasopressin Resistance (AVP-R)” for nephrogenic etiologies This editorial provides both the historical context and the rational for this proposed name change.
- Published
- 2022
- Full Text
- View/download PDF